Thermo Fisher closes $925M One Lambda Dx buyout; Sleep apnea cases soar in China;

 @FierceMedDev: Asia isn't the only growth market: KCI is expanding in Brazil. Release | Follow @FierceMedDev

 @MarkHFierce: Covidien is closing a SC plant and slashing nearly 600 full time and contract jobs. Story | Follow @MarkHFierce

 @DamianFierce: A St. Jude exec says the device tax wasn't the sole cause of the company's job cuts and restructuring. Item | Follow @DamianFierce

> Thermo Fisher Scientific ($TMO) has closed its $925 million acquisition of diagnostics maker One Lambda, a deal expected to add about 10 cents to TF's share price. Release

> Sleep apnea cases are on the rise in China, spurring an increased demand for medical devices and other treatments to address the condition. Story

> Novasys Medical has raised $3.9 million toward development of a nonsurgical medical device to treat urinary incontinence. Item

> Access Scientific gained the FDA's 510(k) clearance for an improved IV catheter that is power injectable and designed to deliver therapy for the entire time a person is in the hospital. Release

> Freshmedx has changed its name to ProLung, as it focuses on commercializing a diagnostic test for the early detection of lung cancer. Item

> Michigan's Tangent Medical Technologies gained FDA clearance to market NovaCath, a new IV system designed to be safer and more effective than typical products used by hospitals. Story

> Medtronic ($MDT) is touting an economic analysis from The Journal of the American College of Cardiology, suggesting its renal denervation system is cost-effective as an option for treatment-resistant hypertension. Release

> AtriCure ($ATRC) is commencing with a three-year post-approval study exploring the use of its Synergy ablation system to treat atrial fibrillation. Release

Biotech News

 @FierceBiotech: Sanofi inks $163M tech pact to speed cancer drugs to clinic. News | Follow @FierceBiotech

 @JohnCFierce: 4SC spotlights partnership talks after liver cancer combo (with Nexavar) extends survival. More | Follow @JohnCFierce

 @RyanMFierce: Viehbacher reminded folks in China that Sanofi sees good emerging market opportunities beyond BRIC countries. More | Follow @RyanMFierce

> GW Pharma IDs promising epilepsy drug in cannabis. Report

> General Dynamics lands a $42M DoD drug development contract. News

> Sanofi snags FDA OK for oral MS drug Aubagio, prices at $45K. News

Pharma News

 @FiercePharma: Sanofi eyes emerging market buyouts beyond the BRICs. Article | Follow @FiercePharma

> J&J picks Bayer AG exec to solve its consumer product mess. News

> Hisun-Pfizer workforce to more than double in size. Report

> Aubagio approval sets Sanofi up with possible blockbuster. More

Pharma Manufacturing News

> Endo recalls potentially 'super potent' painkillers. News

> Sartorius opens $23M bioreactor plant. More

> Canada issues new ranking system for plant violators. Story

> Pfizer injects cloud computing into complex supply chain. Article

Vaccines News

> Potential allergy cure is just under the skin. Article

> HHS awards flu antigen contract to CSL. News

> WHO injects Prevnar 13 with adult prequalification status. More

> Sanofi's dengue vaccine falters in clinical trial. Story